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Abstract
In this study, we retrospectively analysed a total of 605 clinical isolates from six
West or Central African countries (Benin, Cameroon, Central African Republic,
Guinea-Conakry, Niger and Senegal). Besides spoligotyping to assign isolates to
ancient and modern mycobacterial lineages, we conducted phenotypic drug-
susceptibility-testing for each isolate for the four first-line drugs. We showed that
phylogenetically modern Mycobacterium tuberculosis strains are more likely
associated with drug resistance than ancient strains and predict that the currently
ongoing replacement of the endemic ancient by a modern mycobacterial population
in West/Central Africa might result in increased drug resistance in the sub-region.
Introduction
Tuberculosis is one of the most important infectious diseases worldwide. In 2012,
the World Health Organization (WHO) estimated 8.6 million newly infected cases
and 1.3 million deaths globally, with Asia and Africa carrying the major burden of
disease. Moreover, as of 2012, Africa did not reach WHO mortality and
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prevalence targets, and the emergence of drug resistance is a pressing public health
concern [1].
The advent of modern single nucleotide polymorphism (SNP)-based phylogeny
not only lead to a conclusive classification of the Mycobacterium tuberculosis
complex (MTBC) into seven major human lineages, but also demonstrated that
Africa was the geographic origin of all known lineages and the global TB
pandemic [2]. Several authors have shown that phylogenetically distinct
‘‘modern’’ strains (lineages 2, 3 and 4 – also known as East Asian, East-African
Indian and Euro-American lineages) branched off from the existing ‘‘ancient’’
African strains (lineages 1, 5, and 6 – also known as Indo-Oceanic lineage, M.
africanum West Africa 1 and 2) and were globally dispersed paralleling the human
out-of-Africa migration [2, 3]. While active transmission of the two ancient M.
africanum lineages has only been detected in West Africa, modern lineages spread
around the world and were later re-introduced into Africa with arrival of the
colonial powers [2].
West-, and parts of Central Africa, indeed have an intriguing mycobacterial
population structure, as they are the only regions worldwide where all three
ancient lineages 1, 5 and 6 are endemic. However, recent publications from
various countries observed an interesting trend: the replacement of ancient
lineages with modern strains. This phenomenon was first described in Guinea-
Bissau, where M. africanum West African 2 decreased from 51% to 39% between
1989–2008 (19 years), supported by declines in prevalence of M. africanum
lineages observed in Coˆte d’Ivoire, Ghana and Cameroon, amongst others
[4, 5, 6, 7]. The speed of this replacement is remarkable in evolutionary terms, as
mere decades ago ancient lineages contributed up to half of all TB cases in some
areas [4, 5], where prevalence has now declined to a small proportion of all cases
[5].
We hypothesized that this major bacterial population shift may impact on TB
control in the sub-region. Such an assumption is reasonable as lineages/families
tend to vary in phenotypes, potential to transmit, or ability to cause disease
[8, 9, 10]. As drug resistance is of major public health relevance, we focused on the
question whether ancient strains are less likely associated with drug resistance, as
has been suggested for lineage 1 in India [11]. If so, then the presently ongoing
transition towards modern strains might result in increased drug-resistance in
West and Central Africa.
Materials and Methods
Sample collection
The samples analysed within this retrospective study had drug-susceptibility
testing (DST) done on arrival, prior to storage at the Institute of Tropical
Medicine (ITM) in Antwerp and originated from various study sites and time
periods (see Table 1 and S1 Table for detailed information). While samples from
Benin, Senegal and Guinea-Conakry were collected as part of the Oflotub study,
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samples from Cameroon, Niger and the Central African Republic were collected
for quality assurance by the ITM supra-national Reference Laboratory. Ethics
permissions were obtained from the ITM Institutional Review Board.
Drug-susceptibility testing (DST)
To determine the drug resistance profile of each isolate we applied phenotypic
drug-susceptibility testing (DST) using the proportion method. Isolates were
grown at 37 C˚ on Lo¨wenstein-Jenssen slopes containing either rifampicin (RMP)
1 mg/ml, isoniazid (INH) 0.2 mg/ml, ethambutol (EMB) 2 mg/ml or streptomycin
(SM) 4 mg/ml [12, 13].
Spoligotyping and lineage assignment of isolates
To classify isolates into lineages, boiled culture lysates were prepared and
spoligotyped as described elsewhere [14]. Based on the binary spoligotype codes,
lineage assignment to distinguish modern from ancient strains was performed
using the publicly available online package ‘‘TBLineage’’ [15]. The spoligotype
international identifier (SIT) number was assigned using SITVITweb (http://www.
pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/) [16].
Statistical analysis
As differing sampling protocols resulted in the inclusion of isolates from patients
with differing treatment history (new/retreatment cases) (see Table 1), we
adjusted for that variable in any analysis conducted. To determine the association
between mycobacterial lineage and drug-susceptibility we conducted a logistic
regression and calculated the Mantel-Haenszel Odds Ratio (OR) and 95%
Confidence Intervals, adjusted for treatment history of patients.
Table 1. Geographical origin and treatment history of the included patient samples (n5605).
Country Treatment history
New cases Retreatment cases Total
no. (%) no. (%) no. (%)
Benin 43 (9.7%) 43 (26.5%) 86 (14.2%)
Cameroon 145 (32.7%) 20 (12.3%) 165 (27.3%)
Central African Republic 102 (23%) - 102 (16.9%)
Guinea Conakry 120 (27.1%) - 120 (19.8%)
Niger - 53 (32.7%) 53 (8.8%)
Senegal 33 (7.4%) 46 (28.4%) 79 (13.1%)
Total 443 (100%) 162 (100%) 605 (100%)
doi:10.1371/journal.pone.0110393.t001
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Results and Discussion
Six hundred and five MTBC isolates of new and retreatment cases, from two
Central and four West African countries were included into this study (Table 1).
A detailed description of each isolate, its origin, time of sampling, DST profile and
spoligotype international type (SIT) can be found in S1 Table. Although
treatment history of patients was not a significant confounder in our dataset (data
not shown), we still considered it in our final analysis. Combining obtained
spoligotyping and DST data, and conducting a multivariate analysis adjusted for
treatment history (new/retreatment cases), we found a strong association between
lineage and drug resistance (Table 2). Specifically, strains belonging to modern
lineages were more likely resistant to any of the tested drugs compared to ancient
strains (adjusted Odds Ratio (OR), 95%CI53.20 (1.56–6.54), p50.0008). When
analysing results by individual drugs, we found that this result was mainly driven
by the higher risk of resistance towards INH and SM (adjusted OR 95%CI52.71
(1.27–5.77), p50.0073 for INH and adjusted OR 95%CI52.69 (1.23–5.85),
p50.0095 for SM) (Table 2). The association was not demonstrated for RMP and
EMB, nor for multi-drug-resistant TB (MDR-TB) isolates, which constituted
17.7% of the total sample.
Although previous publications demonstrated an association between lineage
and drug-susceptibility in other parts of the world before [11], it was not known
whether these results can be generalized and extrapolated to West and Central
Africa and its geographically highly restricted ancient mycobacterial population
that mainly consists of M. africanum isolates. Interestingly, our results confirmed
and reproduced these recent findings and demonstrated that the introduced
modern strains have increased potential to develop INH- and SM-resistance,
when compared to the endemic ancient African lineages. Replacement of
‘‘susceptible’’ ancient strains by resistant modern strains will thus likely lead to
higher prevalence of resistant mycobacteria. This is an important finding
especially for public health practitioners in West and Central Africa. Although
,10% of the analyzed isolates in the current study were ancient strains, suggesting
that the lineage replacement has already taken place, there are several West
African countries, such as Gambia, Guinea-Bissau, Ghana, Sierra Leone, Mali and
Nigeria, in which ancient strains remain an important cause of tuberculosis
[4, 7, 9, 10, 17, 18, 19, 20]. In these very settings M. africanum can still be
responsible for up to one third of pulmonary TB, and further replacement by
modern M. tuberculosis, with an increased risk of resistance to at least one drug
(adjusted OR 3.2, Table 2), may seriously complicate TB case management and
control strategies. For instance, the predicted elevated INH resistance prevalence
and the use of INH and RMP in the continuation phase of current shortcourse
treatment for 4 months might ultimately result in increased RMP resistance as
well. Although we have not found any association with MDR-TB yet, probably
due to the limited number of ancient strains and lack of statistical power, INH
resistance was already shown to increase the likelihood of acquiring additional
RMP resistance before [21]. In addition, systematically treating patients with
Mycobacterial Lineage and Antibiotic Resistance
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treatment failure with SM in absence of DST might not be appropriate if
prevalence of SM resistance is increasing.
Although we successfully confirmed the described association between ancient
strains and drug-susceptibility [11] in our research area in West and Central
Africa, possible limitations of our study include the retrospective approach and
the low proportion of identified ancient lineages. To conclusively demonstrate
causation between mycobacterial lineage and drug-resistance a prospective
longitudinal large-scale multi-centered study needs to be conducted.
The reason for the observed emergence of modern strains is elusive, however it
was found that these lineages progress to disease faster [8]. This was hypothesized
to provide an adaptation to the overcrowding of humans in cities, in which new
susceptible hosts are in abundance and there is no selective advantage to delay
progression until a new generation of hosts becomes available. Due to the
increased urbanization in Africa, modern strains may have a selective advantage
over ancient, ‘‘rural’’ strains. Another explanation could be that modern strains
are more likely to develop drug resistance and the increased roll-out of drug-based
TB control programs in West and Central Africa, with higher levels of drug
pressure, could potentially select for resistant lineages. Similarly, it could be
conceivable that BCG vaccination is more efficiently protecting against ancient
than modern mycobacterial lineages, due to the closer phylogenetic relatedness of
these ancient lineages to the M. bovis BCG vaccine strains [22]. However, no such
correlation was found in previous studies from The Gambia [23] and since the
present dataset was limited to bacterial data and did not include the BCG status of
the patients, we were not able to test this hypothesis in the present study.
Independent of exact mechanisms triggering the replacement of ancient by
modern strains, our findings predict that ongoing mycobacterial population
dynamics might accelerate the emergence of antibiotic-resistance and should be
considered by public health professionals when planning and evaluating drug
resistance control programs in West and Central Africa.
Table 2. Association between modern (lineages 2, 3, 4) and ancient (lineage 1, 5, 6) mycobacterial lineages and drug-susceptibility testing (DST), overall
resistance and stratified by individual drugs.
Total no. (%) Modern no. (%) Ancient no. (%)
Adjusted Odds Ratio
OR (95% CI)* p-value
DST profile
Any resistance 226 (62.6%) 214 (39.5%) 12 (19%) 3.20 (1.56–6.54) 0.0008
Resistance to individual drugs
Isoniazid 178 (29.4%) 168 (31.0%) 10 (15.9%) 2.71 (1.27–5.77) 0.0073
Ethambutol 85 (14.0%) 79 (14.6%) 6 (9.5%) 1.80 (0.68–4.74) 0.2286
Rifampicin 112 (18.5%) 104 (19.2%) 8 (12.7%) 1.78 (0.79–4.01) 0.1574
Streptomycin 177 (29.3%) 167 (30.1%) 10 (15.9%) 2.69 (1.23–5.85) 0.0095
MDR 107 (17.7%) 99 (18.3%) 8 (12.7%) 1.66 (0.74–3.74) 0.2130
Total 605 (100%) 542 (100%) 63 (100%) - -
*Mantel-Haenszel OR adjusted for treatment history of patients (new/retreatment case).
doi:10.1371/journal.pone.0110393.t002
Mycobacterial Lineage and Antibiotic Resistance
PLOS ONE | DOI:10.1371/journal.pone.0110393 December 10, 2014 5 / 7
Supporting Information
Table S1. Genotypic and DST information on all isolates included in the study.
doi:10.1371/journal.pone.0110393.s001 (XLSX)
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